Baruch Ben Dor

Chief Executive Officer & Board Member

Dr. Ben Dor holds a Ph.D. in physics. His experience in the electro optics field dates to 1988, in both the defense sector and in the medical device industry. Dr. Ben Dor was previously the general manager of a startup company (Medibell Medical Vision Technologies) in the field of ophthalmic digital photography leading it through finishing of prototype R&D, beta testing, production setup, and sales and marketing network development.

Prior to Medibell Dr. Ben Dor served as the director of marketing in Medibell’s mother company, CMT Medical (OEM producer of digital X-ray for Toshiba Medical). Dr. Ben Dor gained his international marketing experience as the vascular program director in the marketing department of ESC/Sharplan, a global leader in the field of medical lasers, responsible for a worldwide network of reference sites for sales support, conducting clinical studies, and producing successful marketing campaigns.

Nancy Jean Barnabei

Chief Financial Officer

Ms. Barnabei has over 22 years of finance and accounting experience with both public and private companies in the biotechnology industry. She has served in senior financial positions with several emerging companies in which she played a key role in fundraising and the transition to executing growth strategies. Most recently, Ms. Barnabei served as VP Finance for GenSpera, Inc., where she was responsible for financial and administrative matters, SEC reporting, and fundraising activities.

Previously, Ms. Barnabei served as Chief Financial Officer of Immune Control, Inc. and its successor company, Corridor Pharmaceuticals, Inc., a drug development company. She founded Talkeetna Advisors, LLC in 2005, a consulting and advisory firm specializing in biotechnology companies, where she provided guidance on a variety of matters including strategic planning, budgeting, accounting, cash flow management, equity compensation, employee benefits, and raising of capital. From 2000 − 2004, she was Vice President Finance, Treasurer and Chief Financial Officer at Locus Pharmaceuticals, Inc. Her previous experience includes eight years at Cephalon, Inc., concluding as Corporate Controller. Ms. Barnabei earned a BS in business administration from Northeastern University, Boston, and is a certified public accountant.

Yosef Ben Dor

Vice President of Sales and Marketing

Mr. Ben Dor holds an MBA from INSEAD, and has extensive international experience. He speaks 5 languages and has lived and worked in Asia and Europe for many years. Mr. Ben Dor has a proven record in sales and distribution channel management and significant understanding and experience in building strategic relations with large multinational firms. In his recent position as the director of sales in Russia for Kodak Graphic Arts he grew annual sales from €12M to €60M within 3 years.

Ian Shipway

Vice President of Research and Development and Operations
Mr. Shipway has over 20 years of product development experience focused on medical technology. He has a successful track record of leading multi-disciplined teams and advancing products from concept through commercialization. Working for mostly early stage companies he has gained extensive experience in driving medical devices through the quality requirements and securing the regulatory approvals.

Most recently he was the Senior Director of Operations and Product Development at Photosonix, an early stage company developing an innovative technology utilizing ultrasound and light to treat bacterial biofilms. He drove the development of conceptual models, led the first series of clinical trials and filed a successful pre-submission with the FDA. Previously, Ian held Director level positions in engineering at Neuronetics, Puricore and Animas. At Neuronetics, a pioneer in neuro-stimulation, he enhanced the product to further its competitive advantages and advanced the design for international and clinical research use. At Animas, he joined at its beginning and was key in developing the Engineering department and spearheading the successful launch of multiple versions of an insulin pump system prior to its acquisition by J&J. He earned his BSEE from the University of Western Australia.


Arie Cohen

Board Member

Mr. Cohen has over thirty years of experience as a senior executive in the medical technology industry, compiling a successful track record in growing young companies and corporate operating divisions. Mr. Cohen has been an Operating Executive with SFW Capital Partners, a private equity firm, since 2009.

Previously, he was the President and Chief Executive Officer at CardioNet, a leading wireless medical technology company focused on remote diagnosis and monitoring of cardiac arrhythmias. Mr. Cohen led CardioNet to a successful IPO and secondary offering in 2008. Before joining CardioNet, Mr. Cohen was the Group President at Viasys Healthcare. He led the $450 million Respiratory Care Group overseeing 1200 employees in various locations around the globe. Viasys Healthcare was acquired in 2007 by Cardinal Health for $1.5 billion. Previously, he held executive positions with Respironics, Datascope, and Air-Shields. Mr. Cohen holds a B.S. in Electrical Engineering and an M.S. in Biomedical Engineering from the University of California, Los Angeles.

Prof. Banu Onaral

Chairman of the Board

Dr. Onaral is H. H. Sun Professor of Biomedical Engineering and Electrical Engineering at Drexel University. She holds a Ph.D. in Biomedical Engineering from the University of Pennsylvania and BSEE and MSEE in Electrical Engineering from Bogazici University, Istanbul, Turkey. Dr. Onaral joined the faculty of the Electrical and Computer Engineering Department and the Biomedical Engineering and Science Institute in 1981. She has served as the founding Director of the School of Biomedical Engineering Science and Health Systems since 1997. Dr. Onaral’s academic focus in both research and teaching is centered on signals and systems engineering with special emphasis on biomedical signal processing.

She has led major research and development projects sponsored by the National Science Foundation (NSF), National Institutes of Health (NIH), Office of Naval Research (ONR), DARPA, and Department of Homeland Security (DHS). She supervised many graduate students and has an extensive publication record in biomedical signals and systems. She is the recipient of a number of faculty excellence awards including the 1990 Lindback Distinguished Teaching Award of Drexel University, the EDUCOM Best Educational Software award and the NSF Faculty Achievement Award. Dr. Onaral’s professional services include chair and membership on advisory boards and strategic planning bodies of several universities and funding agencies, including service on the National Science Foundation’s Engineering Advisory Board, and on the proposal review panels and study sections.

Her editorial responsibilities have included service on the editorial board of journals and the CRC Biomedical Engineering Handbook as Section Editor for Biomedical Signal Analysis. She served as the President of the IEEE Engineering in Medicine and Biology Society (EMBS), the largest member-based biomedical engineering society in the world. Earlier, she had organized and chaired the 1990 Annual International Conference of the EMBS and served as the Co-Chair of the 2004 Annual Conference of the Biomedical Engineering Society. She has been a member of the inaugural Board of the American Institute for Medical and Biological Engineering. She is a Founding Fellow of the American Institute for Medical and Biological Engineering and a Fellow of the IEEE and the AAAS.

Peter Chance

Board Member

Mr. Chance is President of Non-Invasive Technology, Inc., a private company that licenses fundamental patents to the diagnostic, non-invasive medical device area. Previously, using his background in artificial intelligence, he began work at Unimation, at the time the nation’s largest and oldest industrial robot manufacturer. Mr. Chance left Unimation with Mr. Weiss, an MIT graduate, to start their own robot manufacturing company, U.S. Robots. After producing its first and second generation assembly robots, the Maker 100 and 200 series, they sold the company to Square D Company, an electrical equipment manufacturer.

Mr. Chance is a proponent of technology, innovation, and change, with a particular interest in the potential of artificial intelligence on the future. Mr. Chance belongs to a five-generation University of Pennsylvania family – he is the son of Dr. Britton Chance, an internationally known scholar and Professor Emeritus in Biochemistry/Biophysics, and nephew of Henry Chance II, a Penn Trustee and President of United Engineers, a family business founded by his grandfather, Edwin M. Chance, himself a graduate in civil engineering at Penn.

Julian Yuan

Board Member

Mr. Yuan is a co-founder and a member of the Board of Directors of AVIVA Biosciences Corp. Mr. Yuan has served as President and CEO of Progressive Group Inc. (PGI) since its inception in 1983. PGI is one of the largest medical device and instrument distributors in Taiwan. In addition, he founded Sino Pharma Hong Kong Ltd. a company focused on pharmaceutical development for the Chinese market as well as Primus Medical (Shanghai) Co. Ltd. which is targeting diagnostic product distribution in mainland China. Mr. Yuan is an entrepreneur with 22 years of experience in the management and marketing of biosciences products, medical devices and instruments. Mr. Yuan received his Bachelor of Science in Chemistry from Chung Yuan University in Taiwan in 1979.